Bone Density and Longevity: Why Your Skeleton Is a Critical Longevity Organ

The skeleton is not a passive scaffold. Bone is living tissue that stores minerals and houses the marrow that makes blood cells. Osteoporosis develops silently over decades, and its first sign is often a fracture. Worldwide, osteoporotic fractures accounted for 0.83% of the global burden of non-communicable disease in 2000, and in Europe they cost more healthy life-years than any common cancer except lung cancer.¹

Bone Physiology: The Remodeling Cycle

Bone is continuously remodelled: osteoclasts break old bone down and osteoblasts lay new bone in its place. In young adults the two are roughly balanced; later in life breakdown exceeds formation, and bone is slowly lost. Bone strength depends not only on how much mineral bone contains but also on its quality, meaning its internal architecture and material.²

Estrogen restrains bone breakdown, so its fall at menopause speeds bone loss. Menopausal hormone therapy counters this: in the Women's Health Initiative trial of 16,608 women aged 50 to 79, estrogen plus progestin reduced hip fractures (hazard ratio 0.66) but raised the risks of breast cancer, stroke and blood clots in the lungs.⁶ Whether hormone therapy suits an individual woman depends on her age, symptoms and risks, and is a decision to make with her doctor.

The Exercise Prescription for Bone

Not all exercise loads bone equally. The LIFTMOR trial was designed around the principle that bone responds best to high-magnitude strains applied at high rates, which heavy resistance and impact training provide.³

In LIFTMOR, 101 postmenopausal women with low bone mass were randomised to 8 months of supervised, twice-weekly, 30-minute high-intensity resistance and impact training or to a home-based, low-intensity programme. Lumbar spine bone density rose 2.9% with the high-intensity training and fell 1.2% in the comparison group; at the femoral neck it rose 0.3% versus a 1.9% fall. Only one adverse event was reported, a minor back spasm.³ The training was closely supervised, which matters for anyone with low bone density.

A 2026 network meta-analysis of 124 randomized trials with 18,429 adults aged 40 and older found that brisk walking or jogging and combined aerobic-resistance exercise probably help preserve bone density, with meaningful benefits at roughly 2 to 3 hours of brisk walking or jogging a week. In the fracture trials, mixed aerobic exercise and mind-body exercise may also reduce fracture risk, though the certainty of evidence was low.¹³

Nutrition for Bone Density

Calcium (1,000 to 1,200 mg a day from food and supplements combined, depending on age and sex) provides the mineral for bone, and vitamin D is needed to absorb it; a blood level of 20 ng/mL or more is sufficient for most people (NIH). Protein supplies the collagen framework of bone; for people over 65, the PROT-AGE expert group recommends at least 1.0 to 1.2 g per kilogram of body weight a day.⁸ For vitamin K2, the best trial evidence is a three-year study of 244 healthy postmenopausal women in which 180 mcg a day of MK-7 reduced the age-related decline in bone mineral density and bone strength.⁴ Magnesium (RDA 310 to 420 mg a day from food and supplements) is also needed for healthy bone.

DEXA Scanning: When and How Often

A DEXA (dual-energy X-ray absorptiometry) scan measures bone mineral density at the lumbar spine and hip. Results are reported as T-scores, the number of standard deviations from young-adult peak bone density: above −1.0 is normal, −1.0 to −2.5 is osteopenia (low bone mass), and −2.5 or lower is osteoporosis.⁵ The US Preventive Services Task Force recommends screening all women 65 and older and postmenopausal women younger than 65 who are at increased risk; it found the evidence insufficient to recommend for or against screening men.⁷ Routine scans for younger adults without risk factors are not part of these recommendations.

Medications That Prevent Fractures

For people with osteoporosis, several prescription drugs reduced fractures in large trials. In women with low bone mass and an existing vertebral fracture, alendronate cut new vertebral fractures from 15.0% to 8.0% compared with placebo.⁹ A once-yearly infusion of zoledronic acid reduced vertebral fractures by 70% and hip fractures by 41% over three years, although serious atrial fibrillation was more common with the drug.¹⁰ Denosumab, an injection every six months, lowered new vertebral fractures by 68% and hip fractures by 40% over three years.¹¹ Stopping it abruptly is risky: in women who stopped denosumab during its main trial, vertebral fractures rose from 1.2 to 7.1 per 100 person-years, back to untreated levels, so anyone stopping should switch promptly to another bone medication.¹² Which treatment fits, if any, depends on an individual's fracture risk and is decided with a doctor.

Derek Giordano

Founder & Editor, IQ Healthspan

Derek Giordano is the founder and editor of IQ Healthspan. A father of four with a lifelong interest in athletics, fitness and the supplement industry, he built the site to show what the research actually supports. Derek is not a physician: articles cite peer-reviewed studies with numbered references you can check, and corrections are logged publicly. Articles are researched, drafted and fact-checked with the help of AI tools, and every claim is checked against the studies it cites. IQ Healthspan has no supplement brand partnerships, affiliate relationships or financial conflicts of interest.

✓

Sources Listed With Numbered Citations

13 references at the end of this article, checked against PubMed; studies link to their PubMed record